Clinical trials: Major Coronary Event
Postoperative Cardiac Complication
VitamIn and oXygen Interventions and Cardiovascular Events
This study examines the risks and benefits of antioxidants and normal versus high inspiratory oxygen fraction during anaesthesia.
- Trial name
- VIXIE (NCT03494387)
- Testing
- Oxygen, Antioxidants
- Where
- 4 sites in Denmark
- Volunteers
- 600 people
- Sponsor
- University Hospital Bispebjerg and Frederiksberg
Major Adverse Cardiac-cerebral-kidney Event
MACE and First Operating Room Systolic Blood Pressure in Patients Undergoing Non-cardiac Surgery Implications for the Hypertension Threshold
To find the threshold of First operating room SBP above which MACE risk increases.
- Trial name
- NCT03185598
- Volunteers
- 90,342 people
- Sponsor
- Peking University First Hospital
Death, Myocardial Infarction
A Trial Evaluating Vitamin D Normalization on Major Adverse Cardiovascular-Related Events Among Myocardial Infarction Patients
This study evaluates whether achieving 25-hydroxyvitamin D (25[OH] Vit D) levels (>40 ng/mL) among myocardial infarction patients will result in a reduction of cardiovascular-related adverse events.
- Conditions
- Death, Myocardial Infarction, Cerebral Vascular Accident, Heart Failure Hospitalization
- Trial name
- TARGET-D (NCT02996721)
- Testing
- Vitamin D3
- Where
- United States
- Volunteers
- 634 people
- Sponsor
- Intermountain Health Care, Inc.
Coronary Artery Disease, Coronary Restenosis
Systemic Treatment With Everolimus for the Prevention of MACE After Bare Metal Stent Implantation
The purpose of the present study is to provide the first in-human safety and efficacy evaluations of systemic oral anti-proliferative Everolimus therapy compared to placebo in patients treated by bare metal stents for significant…
- Trial name
- NCT00426049
- Testing
- Everolimus
- Where
- Germany
- Volunteers
- 484 people
- Sponsor
- German Heart Institute
Non-obstructive Coronary Artery Disease
Endothelial Function Guided Therapy in Patients With Non-obstructive Coronary Artery Disease
The purpose of this study is to systematically evaluate the clinical application value of vascular endothelial function examination in patients with non-obstructive coronary artery disease.
- Trial name
- EndoFIND (NCT04013204)
- Testing
- Endothelial function guided therapy
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Peking University
Dyslipidemia, High Risk Coronary Artery Disease
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With High Risk Coronary Artery Disease (FORWARD)
The primary objective was to evaluate the effect of treatment with evolocumab on the risk for cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization, whichever…
- Trial name
- FORWARD (NCT04087915)
- Testing
- Evolocumab
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Beijing Anzhen Hospital
Coronary Artery Disease
Tissue-Type Plasminogen Activator (t-PA) Release Predicts Major Adverse Cardiac Events (MACE) in Patients With Non-critical Coronary Artery Disease
Coronary artery disease is the leading cause of death in USA. Contemporary cardiac care has substantially reduced mortality and morbidity in patients with severe coronary artery disease.
- Trial name
- NCT00868855
- Testing
- Bradykinin
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Vanderbilt University
Coronary Artery Disease, Type 2 Diabetes Mellitus
Comparison Between Pioglitazone and SES With type2 DM
Drug-eluting stents have been shown to decrease restenosis, but were associated with an increased rate of death, as compared with bare-metal stents.
- Trial name
- NCT00482183
- Testing
- Pioglitazone
- Volunteers
- 38 people
- Sponsor
- Showa University
Percutaneous Coronary Intervention, Peripheral Endovascular Intervention
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
V-INTERVENTION will evaluate the effectiveness of inclisiran in preventing major cardiovascular and limb events in patients receiving percutaneous coronary or peripheral arterial revascularization.
- Trial name
- V-INTERVENTION (NCT06909565)
- Testing
- Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
- Where
- 147 sites in United States
- Volunteers
- 6,000 people
- Sponsor
- Duke University
Acute Coronary Syndrome
The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial
This study will test whether darapladib can safely lower the chances of having a cardiovascular event (such as a heart attack or urgent coronary revascularization (e.g.
- Trial name
- SOLID-TIMI 52 (NCT01000727)
- Testing
- Darapladib 160 mg, Standard Therapy
- Where
- 914 sites in United States, Argentina and 34 more
- Volunteers
- 13,026 people
- Sponsor
- GlaxoSmithKline
Long-term Major Cardiovascular Events, Myocardial Infarction
CardiOvascular Risk and idEntificAtion of Potential High-risk Population in Acute Myocardial Infarction
The purpose of this registry is to evaluate long-term clinical events in patients with acute myocardial infarction who were treated with percutaneous coronary intervention.
- Conditions
- Long-term Major Cardiovascular Events, Myocardial Infarction, Percutaneous Coronary Intervention
- Trial name
- COREA-AMI (NCT02385682)
- Testing
- Percutaneous coronary intervention
- Volunteers
- 4,748 people
- Sponsor
- Kiyuk Chang
Primary Prevention of Atherosclerotic Cardiovascular Disease
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c.) administered on Day 1, Day 90, and every 6 months thereafter in patients at…
- Trial name
- NCT05739383
- Testing
- Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
- Where
- 983 sites in United States, Argentina and 40 more
- Volunteers
- 14,012 people
- Sponsor
- Novartis Pharmaceuticals
Cardiovascular Diseases
ASpirin Use and stAtin Strategy for Primary Prevention in Severe Coronary Calcium Score on Computed Tomography
The primary objective of the ASA-3C trial is to evaluate the role of aspirin and high-intensity statin therapy, respectively, in individuals with severe coronary calcification (coronary calcium score ≥300) to prevent…
- Trial name
- ASA-3C (NCT06676280)
- Testing
- Aspirin, High-intensity statin, Guideline-directed statin therapy
- Where
- 32 sites in South Korea
- Volunteers
- 5,000 people
- Sponsor
- Jung-min Ahn
Pneumonia, Pneumococcal, Myocardial Ischemia
Myocardial Injury and Severe Pneumococcal Pneumonia
Hypothesis: The "novo" cardiovascular events (CVE)in patients with severe community-acquired pneumonia (CAP) are frequent (17%) and could be associated with both direct pneumococcal myocardial invasion, toxin delivery…
- Trial name
- NEUMOCAR (NCT03058211)
- Testing
- Echocardiography, Cardiac Magnetic resonance
- Where
- Spain
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Alejandro Rodriguez Oviedo , MD
Acquired Long QT, Ventricular Arrhythmias
Do QT-Prolonging Drugs Cause Major Adverse Cardiac Events in Hospitalized Adults?
There are 28 non-cardiology medications from multiple families costing more than $13 billion annually in Canada, categorized as 'Known' QT-prolonging medications (QTPmeds) based on very low levels of evidence.
- Conditions
- Acquired Long QT, Ventricular Arrhythmias, Torsades de Pointes, Syncope
- Trial name
- QTP-MACE (NCT07374263)
- Where
- 2 sites in Canada
- Volunteers
- 990,000 people
- Sponsor
- St. Joseph's Healthcare Hamilton
Atherosclerosis, Carotid Artery Plaque
New Technologies to Determine Carotid Plaque Vulnerability
Hypothesis: Identification of vulnerable atherosclerotic plaques (with or without neovascularization) using carotid CEUS is an independent predictor of MACE (over clinical risk factors, stress echo wall motion results, and…
- Trial name
- CEUS (NCT02224339)
- Where
- United States
- Volunteers
- 216 people
- Sponsor
- Mayo Clinic
Cardiovascular Disease
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
The primary objective is to evaluate the effect of olpasiran, compared to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants at risk for…
- Trial name
- NCT07136012
- Testing
- Olpasiran
- Where
- 252 sites in United States, Australia and 1 more
- Volunteers
- 11,000 people
- Sponsor
- Amgen
Cancer, Drug Toxicity
Atrial Fibrillation in Active Cancer Patients
Atrial fibrillation is a common complication of both cancer and anticancer drugs but the consequences of such events remain poorly known and are not adressed in both phase III oncological trials and cardiological guidelines.
- Conditions
- Cancer, Drug Toxicity, Atrial Fibrillation, Cardiovascular Complication
- Trial name
- AFIB-CANCER (NCT04696081)
- Testing
- occurence of atrial fibrillation
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- University Hospital, Caen
Left Ventricular Remodeling, Plasma Multi-Omics
Prediction of LVAR and MACE in STEMI Though Plasma Multiomics Analysis
To identify plasma multi-omics biomarkers that predict left ventricular adverse remodeling (LVAR) and major adverse cardiovascular events (MACE) in patients with acute ST-segment elevation myocardial infarction, and to…
- Conditions
- Left Ventricular Remodeling, Plasma Multi-Omics, Acute ST-segment Elevation Myocardial Infarction, Immunomics
- Trial name
- NCT06885619
- Testing
- Diagnostic Test: echocardiography and blood collection
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Beijing Anzhen Hospital
Anesthesia, Opioid-Related Disorders
Postoperative and Opioid Free Anesthesia
Since the 1960's, intraoperative administration of opioids is considered a keystone of anesthesia as well as hypnotics and muscle relaxants. Synthetic opioids were introduced to achieve hemodynamic stability during anesthesia.
- Trial name
- POFA (NCT03316339)
- Testing
- Dexmedetomidine, Remifentanil
- Where
- 11 sites in France
- Volunteers
- 316 people
- Sponsor
- Rennes University Hospital